BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

PHI_progress-1024x576-1

BioStock: PHI´s CEO comments on latest advancements

BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.
KT-seminar-The_Promise_of_Regenerqtion_Medicine_and_AI-Fb_bannernew

CERN seminar: The Promise of Regenerative Medicine and AI

During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
Swiss-based Altium major investor BioStock

BioStock: PHI catches eye of major investor

BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Patrik Eschricht and Peter Egelberg shaking hands

BioStock: PHI comments on the new senior positions in the company

BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
1…5678910

Latest News

Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise

On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s (“PHI” or the “Company”) rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.
PHI-accelerates-growth-with-record-order-biostock

BioStock: PHI accelerates growth with record order

PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.
See All News